Gut peptides including GLP-1, PYY, oxyntomodulin, and ghrelin are the most promising peripheral targets for obesity pharmacotherapy, with GLP-1 agonists leading clinical development.
Key findingGut peptide-based obesity drugs including GLP-1 agonists, PYY analogs, oxyntomodulin, and ghrelin antagonists represent the most promising peripheral
What the researchers found
Gut peptide-based obesity drugs including GLP-1 agonists, PYY analogs, oxyntomodulin, and ghrelin antagonists represent the most promising peripheral anti-obesity targets, with GLP-1 showing the most advanced clinical development.
Why it matters
Relevant for glp-1, ghrp, weight-loss, gut-healing.
How the study worked
review study on glp-1, ghrp.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide therapeutics research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Gut peptides and other regulators in obesity.
Seminars in liver disease, 24(4), 335-47
Citation
Scharf, Matthew T; Ahima, Rexford S. (2004). Gut peptides and other regulators in obesity.. Seminars in liver disease, 24(4), 335-47.